Metformin/sulfonylurea - DepomedAlternative Names: Metformin GR/sulfonylurea
Latest Information Update: 15 Jul 2009
At a glance
- Originator Depomed
- Class Antihyperglycaemics; Biguanides; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 09 Feb 2004 Preclinical trials in Type-2 diabetes mellitus in USA (PO)